MARKET

CORT

CORT

Corcept Therapeutics Inc
NASDAQ
73.39
+0.77
+1.06%
Opening 09:48 06/08 EDT
OPEN
72.88
PREV CLOSE
72.62
HIGH
73.99
LOW
72.62
VOLUME
39.10K
TURNOVER
--
52 WEEK HIGH
91.00
52 WEEK LOW
28.66
MARKET CAP
7.88B
P/E (TTM)
206.91
1D
5D
1M
3M
1Y
5Y
1D
Reported Saturday, CATALYST Trial Data Show Korlym Reduces HbA1c By 1.3% And Body Weight By 5.1 Kg In Hypercortisolism Patients With Difficult-To-Control Diabetes
Benzinga · 16h ago
Corcept announces presentation of new data from Catalyst, Momentum trials
TipRanks · 1d ago
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Barchart · 2d ago
Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million
PUBT · 4d ago
Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million
PUBT · 5d ago
Corcept CFO Atabak Mokari sells 40,000 shares for USD 2.8 million
PUBT · 5d ago
Corcept Faces Amended Qui Tam Complaint After DOJ Exit
TipRanks · 5d ago
Corcept Therapeutics Discloses Amended Complaint Filed By Former Employee, Will Defend Itself Against Claims
Benzinga · 5d ago
More
About CORT
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. It is also conducting advanced clinical trials in patients with solid tumors, Amyotrophic Lateral Sclerosis (ALS) and liver disease. It operates through the discovery, development and commercialization of the pharmaceutical products segment. It sells Korlym and a generic version of Korlym in the United States using sales representatives to call on physicians caring for patients with hypercortisolism (Cushing’s syndrome). The Company's portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. It sells and distributes Lifyorli in the United States. It is developing its proprietary, selective cortisol modulator, relacorilant, as a treatment for patients with hypercortisolism.

Webull offers Corcept Therapeutics Inc stock information, including NASDAQ: CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CORT stock methods without spending real money on the virtual paper trading platform.